Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance-Reference-Cited by-同舟云学术

Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance

Published:2018-10 Issue:5 Volume:85 Page:561-567
ISSN:1297-319X
Container-title:Joint Bone Spine
language:en
Short-container-title:Joint Bone Spine

Author:

Scherlinger Marc^ORCID,Germain Vincent,Labadie Céline,Barnetche Thomas,Truchetet Marie-Elise,Bannwarth Bernard,Mehsen-Cetre Nadia,Richez Christophe,Schaeverbeke Thierry

Funder

Pfizer

Publisher

Elsevier BV

Subject

Rheumatology

Reference21 articles.

1. Evolution of treatment for rheumatoid arthritis;Upchurch;Rheumatology,2012

2. Biosimilars for the management of rheumatoid arthritis: economic considerations;Gulácsi;Expert Rev Clin Immunol,2015

3. update of the EULAR recommendations for the management of rheumatoid arthritis: a utopia beyond patients in low/middle income countries?;Misra;Ann Rheum Dis,2017

4. Switching between epoetins: a practice in support of biosimilar use;D’Amore;Biodrugs,2016

5. Switching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience from Sweden;Flodmark;Biol Ther,2013

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study;The Lancet Rheumatology;2024-07

2. Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA;Rheumatology;2023-09-06

3. Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database;BioDrugs;2023-06-06

4. Switching between Originators and Biosimilars in Dermatology: A Systematic Review of Real-World Clinical Studies;Biologics;2023-04-27

5. Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries;Rheumatology and Therapy;2023-01-12